MRK

Merck Nachrichten

92,55
1,15 (1,26%)

Upgrade auf Real-Time

Regelmäßiger Markt

FDA advisors recommend authorization of Merck COVID antiviral pill molnupiravir

To read the full story on Seeking Alpha, click here.

Merck (NYSE:MRK)
Historical Stock Chart
Von Jul 2022 bis Aug 2022

Click Here for more Merck Charts.

Merck (NYSE:MRK)
Historical Stock Chart
Von Aug 2021 bis Aug 2022

Click Here for more Merck Charts.

News Merck and Co Inc

Merck & Company (MRK) Receives a Buy from Mizuho Securities
Donnerstag 18 August 2022 (2 Tage vor) • TipRanks

Merck Reaches Collaboration Deal With Orna Therapeutics of Up to $3.75 Billion
Dienstag 16 August 2022 (3 Tage vor) • Dow Jones News

FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
Dienstag 16 August 2022 (3 Tage vor) • Business Wire

Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
Dienstag 16 August 2022 (3 Tage vor) • Business Wire

The Power of Science to Stop a Killer
Montag 8 August 2022 (2 Wochen vor) • InvestorsHub NewsWire

Quarterly Report (10-q)
Freitag 5 August 2022 (2 Wochen vor) • Edgar (US Regulatory)

Statement of Changes in Beneficial Ownership (4)
Donnerstag 4 August 2022 (2 Wochen vor) • Edgar (US Regulatory)

LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Donnerstag 4 August 2022 (2 Wochen vor) • Business Wire

Credit Suisse Sticks to Their Buy Rating for Merck & Company (MRK)
Donnerstag 4 August 2022 (2 Wochen vor) • TipRanks

Merck: Two Phase 3 Keytruda Studies Miss Targets
Mittwoch 3 August 2022 (2 Wochen vor) • Dow Jones News

Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Mittwoch 3 August 2022 (2 Wochen vor) • Business Wire

Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Mittwoch 3 August 2022 (2 Wochen vor) • Business Wire

Weitere Merck and Co Inc News-Artikel

Kürzlich von Ihnen besucht

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

FX

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

Melden Sie sich bei ADVFN an

Jetzt registrieren

Der Markt LS (Lang&Schwarz) wird als Realtime Indikation kostenlos angezeigt und bietet Ihnen außerbörsliche Realtime Aktienkurse in der Zeit von Mo-Fr 08:00 bis 23:00, Samstags 10:00 bis 13:00 und Sonntags an.
NYSE und AMEX Kurse sind um mindestens 20 Minuten zeitverzögert.
Alle weiteren Kurse sind um mindestens 15 Minuten zeitverzögert, sofern nicht anders angegeben.

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V:de D:20220819 16:32:25